Safety Study of Erythropoietin (EPO) in Parkinson's Disease

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is safe in the treatment of patients with Parkinson's Disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: International Center for Neurological Restoration, Cuba
• Collaborator: Centro de Immunologia Molecular, Cuba
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Hohen and Yahr´s Scale between I and III

• One or more years of evolution of PD,

• Good response to levodopa (more that 30 % of change)valued in motor UPDRS

• An acceptable general health status,

Exclusion Criteria:

• Chronic psychiatric or other neurological diseases.

• Previous polyglobulin

• Hematocryte, same or inferior to 50